Stimulant Use Disorder Objectives

1) Recognize that there are no specific pharmacological interventions for relapse prevention or withdrawal management for stimulant use disorder

| | Abstinence | Use | Retention | Harms |
|--|---|----------|-----------|-------|
| All Antidepressants | ** | Ø | ** | * |
| Aminoketone: Bupropion | * | * | ** | Ø |
| Atypical Antidepressant: Mirtazapine | NA | ø | Ø | Ø |
| SSRI: Sertraline | ø | NA | Ø | NA |
| Atypical Antipsychotics: Aripiprazole | ø | * | Ø | Ø |
| Psychostimulants and Other Medications for ADHD | | | | |
| All Psychostimulants: | * | Ø | * | NA |
| Modafinil, Dexamphetamine, Methylphenidate | | | | |
| Methylphenidate | NA | * | * | NA |
| Atomoxetine | NA | Ø | Ø | Ø |
| All Anticonvulsant and Muscle Relaxants: | đ | ø | đ | Ø |
| Baclofen, Gabapentin, Topiramate | ø | <i>پ</i> | ø | Ø |
| Topiramate | NA | * | * | * |
| Medications used for other substance use disorders | | | | |
| Naltrexone | ø | * | * | ** |
| Varenicline | NA | Ø | Ø | Ø |
| Shading represents the direction of effect: | Symbols represent the strength of the evidence: | | | |
| (No color) Unclear | NA No evidence or not applicable | | | |
| Grey No difference | Ø Insufficient | | | |
| Green Evidence of benefit | ★ Low | | | |
| Red Favors placebo | ★★ Moderate | | | |

• While some trials have shown low level evidence for Methylphenidate and Topiramate; it is not sufficient to recommend this routinely to all patients

High

• Naltrexone, Topiramate, Sertraline, Mirtazapine and Psychostimulants can be considered if they are other indications for these medications

2) Learn what contingency management (CM) is and how it can help

- CM is rooted in operant conditioning and is the strongest evidence based treatment we have for stimulant use disorder. It involves rewarding patients for continued attendance in recovery groups and/or negative urine drug screens.
- The most accessible Victoria group is Addictions Outpatient Treatment (AOT) "Changes" CM Group. Patients can self refer though CARES for this 8 week, 1h zoom group.
- 3) Learn to screen for concurrent ADHD in patients with stimulant use disorder
- 1/3 individuals with stimulant use disorder have concurrent ADHD diagnosis
- Prescription amphetamines have clinically significant benefits in promoting abstinence in individuals with stimulant use disorder and co-occurring ADHD diagnosis
- Consider screening via ASRS symptoms checklist for ADHD
- Consider trial of long acting stimulant medication (ex: Vyvanse) if indicated